Improving the clinical trial landscape for Parkinson syndromes in Germany

Abstract Germany has a longstanding tradition of excellence in neuroscience and Parkinson’s research, supported by outstanding academic institutions, specialized clinical centers, and a strong scientific community. Building on this strong foundation, the country now has the opportunity to transform its clinical research landscape into a more integrated ecosystem for Parkinson syndromes. Despite major advances in molecular understanding, biomarker development, and therapeutic innovation, important structural, regulatory, financial, and organizational barriers continue to limit the full translational potential of German Parkinson research. Participants in an expert workshop identified identify recurring challenges, including fragmented trial infrastructures, slow and bureaucratic regulatory procedures, insufficient funding for investigator-initiated clinical research, limited integration of patient organizations, and suboptimal patient recruitment pathways. This workshop-derived perspective outlines a strategic framework to elevate Germany from a country with excellent individual centers to a globally competitive and integrated hub for innovative Parkinson clinical research. Key recommendations include transforming the German Parkinson Study Group into a nationally coordinated, service-oriented trial network; establishing centralized digital and regulatory infrastructures; diversifying public and philanthropic funding; implementing platform and observational trial structures; strengthening incentives for participating centers; and enhancing patient engagement through national registries, decentralized trial approaches, real-world data based evidence surveillance, and systematic integration of patient organizations. The authors argue that Germany must move beyond isolated university-based structures toward a nationally coordinated and highly efficient research ecosystem capable of rapidly delivering disease-modifying and precision medicine trials. Such a transformation could strengthen Germany’s international position in neurodegenerative disease research and accelerate therapeutic innovation for patients with Parkinson syndromes.